Fezolinetant for VMS: a balanced view on efficacy and safety needed - author's reply

Climacteric. 2024 Aug;27(4):436-437. doi: 10.1080/13697137.2024.2370864. Epub 2024 Jul 8.

Authors

Matheus Pedrotti Chavez¹, Eric Pasqualotto¹, Rafael Oliva Morgado Ferreira¹, Alexandre Hohl², Francisco Cezar Aquino de Moraes³, Pedro Henrique Siedschlag Schmidt¹, Anna Luíza Soares de Oliveira Rodrigues⁴, Joao Roberto de Sa⁵

Affiliations

¹ Division of Medicine, Federal University of Santa Catarina, Florianópolis, Brazil.
² Division of Endocrinology, Federal University of Santa Catarina, Florianópolis, Brazil.
³ Division of Medicine, University Center of João Pessoa, João Pessoa, Brazil.
⁴ Division of Medicine, Federal University of Pará, Belém, Brazil.
⁵ Division of Endocrinology, ABC School of Medicine, São Paulo, Brazil.

PMID: 38973476
DOI: 10.1080/13697137.2024.2370864

No abstract available

Publication types

Letter

MeSH terms

Female
Heterocyclic Compounds, 2-Ring / therapeutic use
Hot Flashes* / drug therapy
Humans
Thiadiazoles* / therapeutic use

Substances

fezolinetant
Thiadiazoles
Heterocyclic Compounds, 2-Ring